[Featured Stock] Orient Bio Rises on Highlighted Potential of COVID-19 Gene Editing Treatment
Secured 3rd Generation Gene Editing Technology 'CRISPR-Cas' in 2018
[Asia Economy Reporter Minwoo Lee] Orient Bio is showing strength following news that it possesses 'gene scissors' technology that could aid in the development of treatments for the novel coronavirus infection (COVID-19).
According to the Korea Exchange on the 12th, as of 9:50 AM, Orient Bio's stock price is trading at 636 won, up about 5% from the previous day.
Recently, the Institute for Basic Science (IBS) Genome Homeostasis Research Center, in collaboration with professors from Ulsan National Institute of Science and Technology (UNIST), has been conducting research to block the proliferation of COVID-19 using the third-generation gene scissors, 'CRISPR-Cas13.' As CRISPR gene scissors technology gains attention as a potential COVID-19 treatment, the news that Orient Bio has secured such technology appears to have driven the upward trend.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Previously, in 2018, Orient Bio signed a contract to license CRISPR-Cas9 gene scissors technology for gene editing mouse business from the gene editing technology company ToolGen.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
